UBS Warburg Cuts Immunomedics to 'Hold'

Analyst Andrew Gitkin thinks regulatory obstacles may hinder product development for its lead product, LymphoCide

UBS Warburg downgraded Immunomedics (IMMU ) to hold from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.